Skip to main content
OpenTrials
Completed

NCT Number: NCT07428941

Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions.

This study aims to determine if an artificial intelligence (AI) medical device can help primary care doctors more accurately identify and manage various skin conditions. Skin issues are a frequent reason for doctor visits, but differences in expertise between general practitioners and specialists can sometimes lead to misdiagnoses or unnecessary referrals.

The researchers hypothesized that the information provided by the AI device would increase the true diagnostic accuracy of primary care practitioners for multiple dermatological conditions. To test this, the study followed a prospective, self-controlled design where each participating doctor served as their own comparison.

During the study, 9 primary care physicians evaluated 30 clinical images representing a variety of skin pathologies. For each image, the doctors followed a two-step process:

* First, they provided a diagnosis based only on the image and the patient's medical history. * Second, they were shown the AI's analysis-including the top 5 suggested diagnoses and confidence levels-and asked to provide a final diagnosis.

The study also investigated if the AI could help doctors decide whether a patient truly needs a referral to a specialist or if the condition could be handled remotely via teledermatology. The primary question was whether using this AI support would significantly increase the number of correct diagnoses made by primary care doctors and lead to more efficient patient care.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This detailed description outlines the clinical methodology, technical framework, and data integrity protocols utilized in the investigation of the Legit Health Plus medical device for skin pathologies in primary care.

Study Design and Technical Methodology The research was conducted as a prospective observational and cross-sectional self-controlled study. It utilized a Multi-Reader Multi-Case (MRMC) framework to measure the impact of Computer-Aided Diagnosis (CAD) on clinician performance.

  • Self-Controlled Framework: Each primary care practitioner (PCP) served as their own comparator, providing diagnoses first without and then with device support.
  • Sequential Evaluation Workflow: Participants accessed a secure web-based platform to review 30 clinical cases. For each case, doctors provided an initial diagnosis based on an image and medical history, followed by a final diagnosis after reviewing the AI's top 5 suggested ICD-11 categories and confidence levels.
  • Clinical Decision Support: The study also evaluated clinician decisions regarding dermatology referrals and the feasibility of remote management (teledermatology) based on AI-provided data, such as malignancy indices.
  • Case Distribution: The 30 clinical images represented nine different conditions, including Melanoma, Basal Cell Carcinoma, Psoriasis, and Hidradenitis Suppurativa, all previously confirmed by dermatologists and anatomical pathology.

Quality Assurance and Data Management

To ensure the scientific integrity of the clinical investigation, the following quality and monitoring protocols were implemented:

  • Centralized Case Report Forms (CRF): All data were collected via a secure web platform where entries were time-stamped and stored in a central database.
  • Data Validation and Checks: Validation rules were applied using computer filters to automatically identify missing values or logical inconsistencies. This was supplemented by manual editing and exploratory statistical techniques to detect errors.
  • Monitoring Plan: An independent clinical monitor oversaw the investigation. Monitoring included remote video or telephone meetings every three months to ensure compliance with the Clinical Investigation Plan (CIP) and ISO 14155:2020.
  • Bias Minimization: Random selection of practitioners helped ensure that outcomes were not influenced by pre-existing group characteristics. Standardized protocols ensured all participants were evaluated under identical conditions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Board-certified primary care physicians regardless of their professional experience.
  • High-quality images of patients with different skin conditions.

Exclusion criteria

  • Low-quality images of patients which can not be properly analyzed.

Treatment and study plan

AI-based medical device for aided diagnosis in dermatological conditions

Device

The intervention consists of a Computer-Aided Diagnosis (CAD) software-only medical device that utilizes computer vision algorithms to analyze digital images of skin structures. During the study, healthcare professionals use the tool as a diagnostic support system to assist in the evaluation of complex dermatological conditions.

Primary outcomes

  1. Diagnostic Accuracy for Multiple Dermatological Conditions with and without Artificial Intelligence Support.

    Time frame: Day 1

    This measure evaluates the "Top-1" diagnostic accuracy of primary care practitioners (PCPs). Accuracy is determined by comparing the clinician's identified diagnosis-both before and after receiving the AI's top 5 suggestions-against a confirmed reference standard (confirmed by dermatologists or anatomical pathology).

Secondary outcomes

  1. Change in Dermatology Referral Rate Assisted by Artificial Intelligence.

    Time frame: Day 1

    This outcome validates the percentage of cases that practitioners determine should be referred to a dermatology specialist after reviewing the AI-provided information, including malignancy indices and tool recommendations. The goal is to evaluate if the device helps optimize resource allocation by reducing unnecessary referrals

  2. Percentage of Cases Deemed Manageable via Remote Consultation.

    Time frame: Day 1

    This measure assesses the practitioners' evaluation of whether a case can be confirmed and treated remotely through teledermatology based on the AI analysis. A Pearson's chi-squared test is used to analyze the association between referral necessity and remote consultation feasibility.

Sponsors and collaborators

Lead sponsor

AI Labs Group S.L

Industry

Collaborators

  • Puerta de Hierro University Hospital

Registry information

Official study title

A Multi-Reader Multi-Case (MRMC) Study Assessing the Impact of Legit.Health Plus on the Diagnostic Accuracy and Referral Decision-Making of Primary Care Physicians for Skin Lesions.

Acronym: LegitHealth PH

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Feb 24, 2026
Registry last updated
Feb 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.